Cytyc pays $311 for NovaSure menorrhagia device firm
This article was originally published in Clinica
Executive Summary
Cervical cancer screening firm Cytyc has agreed to pay $311m net in cash for Novacept, a privately owned company that makes and sells a device to treat heavy menstrual bleeding in women who have finished childbearing.